lapatinib has been researched along with ast 1306 in 2 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (ast 1306) | Trials (ast 1306) | Recent Studies (post-2010) (ast 1306) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 18 | 2 | 17 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bai, F; Jiang, H; Li, H; Liu, H; Liu, L; Liu, X; Tong, L; Wang, X; Xie, H; Zhao, Z; Zhou, W | 1 |
Baltazar, F; Barbosa, AM; Cardoso-Carneiro, D; Cury, FP; de Paula, FE; Evangelista, AF; Granja, S; Longatto-Filho, A; Marques, F; Martinho, O; Miranda-Gonçalves, V; Moreira, MA; Reis, RM; Scapulatempo-Neto, C; Silva-Oliveira, R; Zanon, M | 1 |
2 other study(ies) available for lapatinib and ast 1306
Article | Year |
---|---|
Discovery of novel selective inhibitors for EGFR-T790M/L858R.
Topics: Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Drug Discovery; ErbB Receptors; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors | 2012 |
HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.
Topics: Acrylamides; Adenocarcinoma; Antimetabolites; Antineoplastic Agents; Biomarkers, Tumor; Diagnostic Tests, Routine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glucose; Humans; Lapatinib; Quinazolines; Theranostic Nanomedicine; Therapeutic Uses; Uterine Cervical Neoplasms | 2017 |